Drug Profile
Research programme: infectious disease therapeutics - Oncolys BioPharma
Alternative Names: OBP-AI 1; OBP-AI 2Latest Information Update: 30 Sep 2015
Price :
$50
*
At a glance
- Originator Oncolys BioPharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C; HIV infections
Most Recent Events
- 30 Sep 2015 Discontinued for Hepatitis C in Japan (Parenteral) (Oncolys pipeline, September 2015)
- 30 Sep 2015 Discontinued for HIV infections in Japan (Parenteral) (Oncolys pipeline, September 2015)
- 23 Jun 2011 Early research in HIV infections in Japan (Parenteral)